Diarrhea News and Research

Latest Diarrhea News and Research

Bioniche Life Sciences opens new livestock vaccine manufacturing facility

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today officially opened its new Animal Health and Food Safety Vaccine Manufacturing Centre at its corporate headquarters in Belleville, Ontario, Canada.

30 Apr 2011

Penn Nursing, Surgeon General partner to promote breastfeeding awareness in the U.S.

While 75 percent of U.S. babies start out breastfeeding, the U.S. Centers for Disease Control and Prevention reports only 13 percent are exclusively breastfed at the end of six months. Six months of exclusive breastfeeding is the American Academy of Pediatrics' minimum recommendation.

30 Apr 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

30 Apr 2011

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Vertex Pharmaceuticals Incorporated announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.

29 Apr 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

Food poisoning costs the United States billions: Report

According to a new report published Thursday, 14 different pathogens causing food poisoning cost the United States $14 billion annually in terms of human disease. The report comes from the University of Florida Emerging Pathogens Institute that found that out of all the pathogen-food combinations they studied, campylobacter in poultry was the single worst offender, causing more than 600,000 illnesses per year, hospitalizing more than 7,000 people and costing, annually, $1.3 billion and 9,500 quality-of-life years.

29 Apr 2011

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Creative approach can tackle bacterial infections in patients with cystic fibrosis

An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.

25 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Sugar-based vaccine against Helicobacter pylori

A potential vaccine against bacteria that cause serious gastric disorders including stomach cancer may be a step closer following a pioneering study by a University of Guelph chemist.

19 Apr 2011

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly-resistant bacteria, commonly referred to as 'superbugs.'

16 Apr 2011

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

Novocure today announced that the U.S. Food and Drug Administration approved the NovoTTF-100A System for the treatment of adult patients with glioblastoma multiforme brain tumors, following tumor recurrence after receiving chemotherapy.

16 Apr 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Bioniche Life Sciences opens new livestock vaccine manufacturing facility

Penn Nursing, Surgeon General partner to promote breastfeeding awareness in the U.S.

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Food poisoning costs the United States billions: Report

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

Curis reports first quarter net loss of $6.8 million

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Millennium submits two VELCADE sNDAs to FDA

Nausea and vomiting are most feared of all chemotherapy-related side effects

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

Creative approach can tackle bacterial infections in patients with cystic fibrosis

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Rituxan receives FDA approval for treating two rare diseases

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Sugar-based vaccine against Helicobacter pylori

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Diarrhea News and Research

Latest Diarrhea News and Research

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Newsletters you may be interested in